JP2023536462A5 - - Google Patents
Info
- Publication number
- JP2023536462A5 JP2023536462A5 JP2023505922A JP2023505922A JP2023536462A5 JP 2023536462 A5 JP2023536462 A5 JP 2023536462A5 JP 2023505922 A JP2023505922 A JP 2023505922A JP 2023505922 A JP2023505922 A JP 2023505922A JP 2023536462 A5 JP2023536462 A5 JP 2023536462A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- pharmaceutically acceptable
- compound
- week
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058891P | 2020-07-30 | 2020-07-30 | |
| US63/058,891 | 2020-07-30 | ||
| US202063109854P | 2020-11-04 | 2020-11-04 | |
| US63/109,854 | 2020-11-04 | ||
| US202163202242P | 2021-06-02 | 2021-06-02 | |
| US63/202,242 | 2021-06-02 | ||
| PCT/US2021/071048 WO2022027058A1 (en) | 2020-07-30 | 2021-07-29 | Methods of treating mutant lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536462A JP2023536462A (ja) | 2023-08-25 |
| JP2023536462A5 true JP2023536462A5 (https=) | 2024-08-14 |
Family
ID=80036177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505922A Pending JP2023536462A (ja) | 2020-07-30 | 2021-07-29 | 変異体リンパ腫を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11857535B2 (https=) |
| EP (1) | EP4188374A4 (https=) |
| JP (1) | JP2023536462A (https=) |
| KR (1) | KR20230044480A (https=) |
| CN (1) | CN116133692A (https=) |
| AU (1) | AU2021316053A1 (https=) |
| BR (1) | BR112023001638A2 (https=) |
| CA (1) | CA3187255A1 (https=) |
| IL (1) | IL300175A (https=) |
| MX (1) | MX2023001217A (https=) |
| PH (1) | PH12023550237A1 (https=) |
| TW (1) | TW202220653A (https=) |
| WO (1) | WO2022027058A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US20240383887A1 (en) * | 2021-05-07 | 2024-11-21 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| CN115572768B (zh) * | 2022-11-04 | 2023-12-19 | 山东第一医科大学附属省立医院(山东省立医院) | 一种针对弥漫大b细胞淋巴瘤的预后评估及联合治疗 |
| WO2024148049A1 (en) * | 2023-01-04 | 2024-07-11 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| WO2024191788A1 (en) * | 2023-03-10 | 2024-09-19 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| CA2722159C (en) | 2008-04-24 | 2016-04-05 | Newlink Genetics Corporation | Substituted phenylimidazole compounds and their use as ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8921037B2 (en) | 2008-12-16 | 2014-12-30 | Bo Han | PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11542251B2 (en) * | 2018-02-14 | 2023-01-03 | Dana-Farber Cancer Institute, Inc. | IRAK degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN112969696B (zh) * | 2018-11-02 | 2024-06-11 | 达纳-法伯癌症研究公司 | 乙酰化书写器抑制剂的开发及其用途 |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| US20240383887A1 (en) * | 2021-05-07 | 2024-11-21 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
-
2021
- 2021-07-29 CN CN202180062152.2A patent/CN116133692A/zh active Pending
- 2021-07-29 MX MX2023001217A patent/MX2023001217A/es unknown
- 2021-07-29 CA CA3187255A patent/CA3187255A1/en active Pending
- 2021-07-29 JP JP2023505922A patent/JP2023536462A/ja active Pending
- 2021-07-29 TW TW110127954A patent/TW202220653A/zh unknown
- 2021-07-29 IL IL300175A patent/IL300175A/en unknown
- 2021-07-29 PH PH1/2023/550237A patent/PH12023550237A1/en unknown
- 2021-07-29 BR BR112023001638A patent/BR112023001638A2/pt unknown
- 2021-07-29 US US17/444,015 patent/US11857535B2/en active Active
- 2021-07-29 EP EP21848959.9A patent/EP4188374A4/en not_active Withdrawn
- 2021-07-29 WO PCT/US2021/071048 patent/WO2022027058A1/en not_active Ceased
- 2021-07-29 KR KR1020237006759A patent/KR20230044480A/ko not_active Ceased
- 2021-07-29 AU AU2021316053A patent/AU2021316053A1/en not_active Abandoned
-
2023
- 2023-11-22 US US18/517,432 patent/US20240316004A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536462A5 (https=) | ||
| US6576646B1 (en) | Methods for treating cognitive impairments caused by traumatic brain injuries | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2020534263A5 (https=) | ||
| JP2022527398A5 (https=) | ||
| FI3577124T3 (fi) | Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon | |
| ES2202322T3 (es) | Uso de tiazolidinadionas para el tratamiento de la ateroesclerosis y trastornos de la alimentacion. | |
| JP2021530513A5 (https=) | ||
| KR101951220B1 (ko) | 조합 als 치료법 | |
| JP2022508513A5 (https=) | ||
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| JPS5910585A (ja) | スピロスクシンイミド誘導体のアルツハイマ−型痴「ほう」の治療における使用 | |
| NZ541187A (en) | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome P450, such as protease inhibitors | |
| RU2192252C2 (ru) | Применение прамипексола в лечении синдрома усталых ног | |
| JP2022177119A5 (https=) | ||
| JP2021531308A5 (https=) | ||
| WO2014210369A2 (en) | Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents | |
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| JP2023525633A (ja) | コロナウイルス感染症の治療のためのスフィンゴシン経路調節化合物 | |
| AU689783B2 (en) | Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of Parkinson disease | |
| JP2025505261A5 (https=) | ||
| JP2005511571A5 (https=) | ||
| JP6420923B1 (ja) | 医薬 |